SO
VERV

STRS Ohio’s Verve Therapeutics VERV Stock Holding History

STRS Ohio’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$13K – 2037
2023
Q4 		$13K Buy
+1,000
New +$12.4K ﹤0.01% 1864
2022
Q4 		– Sell
-7,100
Closed -$243K – 2077
2022
Q3 		$243K Buy
+7,100
New +$227K ﹤0.01% 1553
2022
Q2 		– Sell
-8,600
Closed -$196K – 2301
2022
Q1 		$196K Buy
8,600
+5,000
+139% +$143K ﹤0.01% 1714
2021
Q4 		$132K Hold
3,600
– – ﹤0.01% 1837
2021
Q3 		$169K Buy
+3,600
New +$212K ﹤0.01% 1815

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

STRS Ohio's VERV Position: Q1 2024 in Review

STRS Ohio sold out of Verve Therapeutics (VERV) in Q1 2024, closing a stake of 1,000 shares — an estimated $13K sold.

STRS Ohio first reported a position in VERV in Q3 2021 and held it in 5 quarters. The position peaked at $243K in Q3 2022. 163 funds tracked by Wall St. Rank hold VERV as of Q1 2024.

  • STRS Ohio reported no remaining Verve Therapeutics position as of Q1 2024 after selling out during the quarter.
  • STRS Ohio sold 1,000 Verve Therapeutics shares in Q1 2024, an estimated $13K.
  • STRS Ohio first reported a position in Verve Therapeutics in Q3 2021 and held it in 5 quarters.
  • STRS Ohio's Verve Therapeutics position peaked at $243K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2024.

Based on STRS Ohio's 13F filing for Q1 2024, filed 13 May 2024.